Celltrion Pharm said on the 5th that operating profit on a consolidation basis last year was 56.1 billion won, up 50.7% from a year earlier. Revenue for the same period rose 12.3% to 536.4 billion won, marking the highest performance since the company was founded.
The company cited stable revenue growth of key products and the early establishment of new products in the domestic market as the backdrop for improved results. Despite workforce expansion and higher research and development expenses, it said profitability improved as cost structures were streamlined and the prefilled syringe (PFS) production facility continued to run at maximum capacity.
Revenue in the chemical institutional sector totaled 214 billion won for the year. The hepatic agent "Godex Capsule" and the hypertension treatment "Dilatrend Tablet" posted revenue of 68.4 billion won and 57.4 billion won, up 2.4% and 14.3% from a year earlier, respectively. In-house manufactured products also maintained stable growth, and revenue from diabetes treatments such as "Nesina" and "Actos" rose 16.2% to 34.8 billion won.
Revenue in the biosimilar institutional sector came to 130.6 billion won, up 50.8% from a year earlier. The three existing biosimilars—"Remsima," "Herzuma," and "Truxima"—posted a combined 79.7 billion won in revenue, driving performance growth.
The oncology biosimilar "Vegzelma" expanded prescriptions at major tertiary hospitals, generating 12.7 billion won in revenue, up 235% from a year earlier. The autoimmune disease treatment "Yuflyma" also secured a foothold in the market, with revenue up 114.8% to 7.7 billion won.
New products launched domestically last year also showed standout growth. Six new products—the autoimmune disease treatments "Steqeyma" and "AptoZma," the ophthalmic disease treatment "Eydenzelt," the allergic asthma treatment "OMLYCLO," and the bone disease treatments "Stovoclo" and "Osenbelt"—posted a combined 30.5 billion won in revenue. That accounts for 23.3% of total biosimilar revenue.
In the contract manufacturing institutional sector, demand increased across the entire biosimilar lineup, including the subcutaneous infliximab treatment "Remsima SC" (U.S. brand name Zymfentra), as well as "Herzuma" and "Truxima." As a result, the PFS production facility maintained maximum utilization, with revenue up 2.8% year over year to 139.6 billion won.
Celltrion Pharm plans to continue performance growth this year by strengthening product competitiveness and maximizing contract manufacturing utilization. Along with expanding the market for new biosimilars, it will focus on improving profitability of chemical medicines centered on in-house manufactured products such as "Nesina," "Actos," and "Edarbi."
A company official said, "Last year, with top-line growth alongside improvements in expenses and cost structures, we surpassed 500 billion won in revenue for the first time, and operating profit rose more than 50% from a year earlier," adding, "This year, we will continue stable, profitability-focused growth by strengthening the competitiveness of core products."